Trending...
- New Rochelle Police Arrest Suspect in Child Grooming Sting Operation
- New Rochelle Police Arrest Two Following Assault at Gas Station
- Corcoran DeRonja Real Estate Welcomes Mechelle Fuquay as Its Newest Broker
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) ("Atara" or the "Company").
The investigation concerns whether Atara Biotherapeutics, Inc. and certain of its officers and/or directors have engaged in securities fraud.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
More on Nyenta.com
Atara announced on January 16, 2025, that it had received "a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the EBVALLOTM (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen."
According to the Company, "The CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO."
The FDA took the additional step of placing a clinical hold on the biotech's active Investigational New Drug applications due to the same manufacturing concerns that led to Ebvallo's rejection. In addition to Ebvallo, the hold also affected the company's allogeneic CD19 CAR T therapy ATA3219, which was testing for non-Hodgkin's lymphoma and systemic lupus erythematosus. Atara had to suspend screening and enrollment of new study patients in both programs. Only those already enrolled in trials who could "potentially derive clinical benefit" can continue receiving treatment under ongoing study protocols.
On January 16, 2025, the stock fell $4.82 per share, to close at $7.62, a decline of 39%.
The company has subsequently announced, on January 27, 2025, that it would cut 50% of its workforce by June of this year.
More on Nyenta.com
Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly lauded by the courts, which have appointed it to major positions in complex securities, multi-district and consolidated litigation.
If you wish to discuss this investigation or have any questions regarding your rights and interests, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at [email protected].
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) ("Atara" or the "Company").
The investigation concerns whether Atara Biotherapeutics, Inc. and certain of its officers and/or directors have engaged in securities fraud.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
More on Nyenta.com
- Yonkers Mayor Spano Appoints Hope Hollinsworth-Coaxum Director of the Office of Constituent Services
- Elevate Local Launches to Help Tennessee Small Businesses Grow Online with Expert SEO and Digital Marketing
- BookCAMP 2025: The Trade Show for Independent Authors and Publishers
- Creep by Radiohead Guitar Chord Tutorial Now Available
- Olga Torres Once Again Recognized as a Top Advisor by Foreign Investment Watch
Atara announced on January 16, 2025, that it had received "a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the EBVALLOTM (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen."
According to the Company, "The CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO."
The FDA took the additional step of placing a clinical hold on the biotech's active Investigational New Drug applications due to the same manufacturing concerns that led to Ebvallo's rejection. In addition to Ebvallo, the hold also affected the company's allogeneic CD19 CAR T therapy ATA3219, which was testing for non-Hodgkin's lymphoma and systemic lupus erythematosus. Atara had to suspend screening and enrollment of new study patients in both programs. Only those already enrolled in trials who could "potentially derive clinical benefit" can continue receiving treatment under ongoing study protocols.
On January 16, 2025, the stock fell $4.82 per share, to close at $7.62, a decline of 39%.
The company has subsequently announced, on January 27, 2025, that it would cut 50% of its workforce by June of this year.
More on Nyenta.com
- $300 Million in Milestones; Double-Digit Royalties; Neurospa LOI for Expansion of International Psychiatry Clinics plus NDA Filed with FDA on New Drug
- Rosann Santos Becomes Licensed Speaker with Impostor Syndrome Institute to Offer Rethinking Impostor Syndrome™ Program
- COSRX Offers Unmissable Deals in Amazon's Big Spring Sale 2025
- Spartan Investigations Partners with Dallas Law Enforcement to Combat Human Trafficking
- Torture in the Troubled Teen Industry, Death by Deliberate Indifference Report
Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly lauded by the courts, which have appointed it to major positions in complex securities, multi-district and consolidated litigation.
If you wish to discuss this investigation or have any questions regarding your rights and interests, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at [email protected].
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
Filed Under: Business
0 Comments
Latest on Nyenta.com
- AMERICANS FOR CITIZEN VOTING: NEW YORK COURT OF APPEALS: ONLY CITIZENS VOTE
- Announcing The Must-Read Crypto Playbook Of 2025!
- World Premiere of "Prelude for Caroline" by Leonardo Le San Unites Music and Art
- Faruqi & Faruqi Reminds Alarum Technologies Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 15, 2025 - ALAR
- Nanomi Receives CMO Award for Life Science Leadership in Drug Delivery USA - English USA - English
- Etan Polinger Officially Recognized As New Mexico's First Certified Ai Consultant
- N/UM Named Oprah Daily's Editor's Choice: A Testament to Luxury, Innovation & Sustainability
- Design Public Group Opens New Luxury Furniture Showroom in New York's Flatiron District
- Expert Law Attorneys Nominates 2025 Personal Injury Firms
- The Ripple Effect Arts Leverages Social Media to Showcase the Benefits of Magic Magnesium Spray, Driving 200% Audience Growth
- America Is Being Ripped Off: It's Time To Take Action Against Fraud & Foreign Exploitation
- Independence Title Honored for Excellence in Fraud Prevention by Stewart Title
- Why Renting a Photo Studio is the Best Choice for Your Next Shoot
- Bloomberg Law Showcases Advanced AI Solutions and Enhanced Workflow Tools at Legalweek
- Why Every Photographer Should Have Access to a Professional Photo Studio
- Dentaluxe's New Website Launch!
- Cousins Maine Lobster Makes Albany Debut with New Food Truck
- PawTides.com Partners with Rescue 22 Foundation to Support Veterans and Rescue Dogs
- Pan-Armenian Digital Trade Center Launched on Fastexverse
- Stern Recruiting Launches with a Mission to Revolutionize Talent Acquisition